Day: December 3, 2021

In November 2021 AS Tallink Grupp transported 351 857 passengers, which is an 121.6% increase compared to November 2020. The number of cargo units increased by 28.2% to 35 486 units and the number of passenger vehicles increased by 9.9% to 50 113 units in the same comparison. AS Tallink Grupp passenger, cargo unit and passenger vehicles numbers for November 2021 were the following:  November 2021 November 2020 ChangePassengers 351 857 158 777 121.6%Finland – Sweden 147 383 34 263 330.2%Estonia – Finland 172 228 120 403 43.0%Estonia – Sweden 32 246 3 587 799.0%Latvia – Sweden 0 524 -100.0%       Cargo Units 35 486 27 688 28.2%Finland – Sweden 6 724 5 150 30.6%Estonia – Finland 23 471 18 304 28.2%Estonia – Sweden 5 291 3 929 34.7%Latvia – Sweden 0 305 -100.0%       Passenger Vehicles 50 113 45 613 9.9%Finland...

FirstFarms A/S’ Board of Directors has adopted the following financial calendar for 2022:23 March 2022        Annual report 2021                 26 April 2022           Annual general meeting                 31 May 2022           Interim financial report 1 January – 31 March 2022 24 August 2022       Interim financial report 1 January – 30 June 2022 23 November 2022 Interim financial report 1 January – 30 September 2022Proposals from the shareholders for discussion on the annual general meeting 26 April 2022 shall be in the Board of Directors’ possession at the latest 15 March 2022. Best regards,FirstFarms A/S For further information:Please visit our website www.firstfarms.com or contact CEO Anders H. Nørgaard on telephone +45 75 86 87 87. About FirstFarms:FirstFarms is a Danish stock exchange listed company. We operate FirstFarms...

MONT-SAINT-GUIBERT, Belgium, Dec. 03, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has entered into a subscription agreement with an affiliate of Fortress Investment Group (such affiliate “Fortress”) for the private placement of 6,500,000 ordinary shares for gross proceeds of USD 32.5 million (about EUR 28.7 million). The subscription will take place within the framework of the authorized capital and it is expected to close on or about December 8, 2021, subject to satisfaction of customary closing conditions. Pursuant to the terms of the private placement, the Company will issue the ordinary shares at a...

Solutions 30 and its banks will resume their usual course of collaboration with immediate effect. This decision occurs in the context of the conciliation procedure and follows the publication of the Group’s interim financial report incorporating the auditor’s report on the interim financial statements. Solutions 30 would like to thank its banks for their continued trust and support to the Group throughout this period. About Solutions 30 SE The Solutions 30 group is the European leader in solutions for new technologies. Its mission is to make the technological developments that are transforming our daily lives accessible to everyone, individuals and businesses alike. Yesterday, it was computers and the Internet. Today, it’s digital technology. Tomorrow, it will be technologies that make the world even more interconnected in...

REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SOGosselies, Belgium, 3 December 2021, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it raised EUR 3.3 million in gross proceeds through an equity private placement of 4,832,352 new shares at an issue price of EUR 0.68 per share with existing and new institutional investors. The gross proceeds will be used to advance Bone Therapeutics’ lead orthopedic asset, ALLOB, through mid-stage clinical development. The funds will also support the acceleration of the development...

Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions Three new testing kits are among the first to specify the mutations of the recently discovered Omicron variant, and can help manage the evolving COVID-19 pandemic Use of these new tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines, and public health interventions Roche has analysed the publicly available sequences of the SARS-CoV-2 Omicron variant and concluded that all of our PCR tests correctly identify COVID including the new variantBasel, 3 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics...

Research collaboration with leading acute myeloid leukemia (AML) experts, Professor Ochsenbein and Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital, Switzerland, to support advancement of drug development process MP0533 is designed to target three distinct tumor associated antigens simultaneously to achieve high specificity and broad cancer cell coverage The novel immuno-therapy candidate aims to engage T cells via CD3, a potent immune activatorZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a research collaboration with University of Bern, to advance the development...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021 negotiations with the China National Healthcare Security Administration (“NHSA”), on January 1, 2022 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and will now include SULANDA® (surufatinib). Christian Hogg, Chief Executive Officer of HUTCHMED, said, “We welcome the addition of SULANDA® into the NRDL, along with the renewal of ELUNATE®. The NRDL has made it possible for novel therapies to gain wide reach across the country for diseases with large patient populations.” ELUNATE® was first included in the NRDL on January 1, 2020, for the treatment of metastatic colorectal cancer (“CRC”)....

ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock. Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock at a combined public offering price of $7.00 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The short-term warrants have an exercise price of $9.00 per share, are exercisable immediately, and will expire two years following the date of issuance. H.C. Wainwright & Co. is acting as sole book-running manager for the offering. In addition, Esperion...

New York, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) — BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, Friday, December 3, 2021, under the ticker symbol “BIOSU”. Each unit consists one of the Company’s Class A ordinary shares and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “BIOS” and “BIOSW,” respectively. The...